Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
70 hedge funds and large institutions have $291M invested in Syros Pharmaceuticals, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 31 increasing their positions, 14 reducing their positions, and 9 closing their positions.
121% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 14
89% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 9
13% more funds holding
Funds holding: 62 → 70 (+8)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
35% less capital invested
Capital invested by funds: $446M → $291M (-$156M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$7.54M |
| 2 |
JP Morgan Chase
New York
|
+$3.19M |
| 3 |
Millennium Management
New York
|
+$3.07M |
| 4 |
SCM
Sio Capital Management
New York
|
+$2.72M |
| 5 |
NAMA
Nikko Asset Management Americas
New York
|
+$2.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$22.3M |
| 2 |
6CM
683 Capital Management
New York
|
-$4.46M |
| 3 |
AVM
Arch Venture Management
Chicago,
Illinois
|
-$3.28M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$1.75M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$1.73M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MLICM
76
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$138K | -1,329 | Closed |
|
77
Victory Capital Management
San Antonio,
Texas
| – | -$50K | -481 | Closed |
|
|
TRCT
78
Tower Research Capital (TRC)
New York
| – | -$28K | -269 | Closed |
|
79
Simplex Trading
Chicago,
Illinois
| – | -$3.52K | -58 | Closed |
|
SYRS Hedge Fund Activity: Q4 2019 in Review
70 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q4 2019, worth a combined $291M — down 35% from $446M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new SYRS positions and 9 closed out — a net gain of 8 holders — while 31 added to existing stakes and 14 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $7.54M. The largest seller was Redmile Group, cutting an estimated $22.3M.
- 70 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q4 2019, up from 62 in Q3 2019.
- Funds reported $291M of Syros Pharmaceuticals, Inc. Common Stock stock for Q4 2019, down 35% quarter-over-quarter.
- 17 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q4 2019 and 9 closed out, a net change of +8 holders.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q4 2019 was ARK Investment Management, an estimated $7.54M added.
- The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q4 2019 was Redmile Group, an estimated $22.3M sold.
Based on aggregated 13F filings for Q4 2019.